Novel N-hydroxyguanidine derivatives as anticancer and antiviral agents.
Hydroxyguanidine contains both features of guanidine and hydroxyurea and has antiviral and anticancer activities both in vitro and in vivo. In order to enhance the antiviral and anticancer activity of this compound, a new series of hydroxyguanidine derivatives with the following structures were synthesized: R = NNHC(= NH)NHOH, where R = aromatic or heterocyclic aldehyde. This series of compounds was prepared in order to alter the lipophilic/hydrophilic balance, as well as the electronic and steric properties of hydroxyguanidine. The anticancer activities of the compounds were tested against cultured L1210 cells. The ID50 values of the above compounds are in the range of 7.80-126 microM. They are about 10-fold more active than hydroxyurea and hydroxyguanidine. The antiviral activities were also tested by assaying the inhibition of transformation of chicken embryo fibroblasts infected with Rous sarcoma virus. The ID50 values of these new compounds are in the range of 2.76-195.2 microM. The most active ones are about 100-fold more active than hydroxyguanidine. At the ID50, no apparent toxicity to the cells was noticed.